Does Rallies show Form 4 insider transactions for ALDX?

Yes. Rallies tracks ALDX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ALDX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ALDX. It does not provide personalized investment advice.

ALDX (Aldeyra Therapeutics, Inc.) Stock Analysis - Insider Trades

Aldeyra Therapeutics, Inc. (ALDX) is a publicly traded Healthcare sector company. As of May 21, 2026, ALDX trades at $1.52 with a market cap of $96.51M and a P/E ratio of -2.76. ALDX moved +0.00% today. Year to date, ALDX is -63.44%; over the trailing twelve months it is -34.32%. Its 52-week range spans $1.07 to $7.20. Analyst consensus is buy with an average price target of $5.50. Rallies surfaces ALDX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ALDX stock inside the company?

Recent ALDX insider activity includes DOUGLAS RICHARD bought 70.00K, Alfieri Michael bought 5.00K, Alfieri Michael bought 2.50K, Machatha Stephen sold 22.07K, and PERCEPTIVE ADVISORS LLC sold 3.40M. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ALDX Key Metrics

Key financial metrics for ALDX
Metric	Value
Price	$1.52
Market Cap	$96.51M
P/E Ratio	-2.76
EPS	$-0.56
Dividend Yield	0.00%
52-Week High	$7.20
52-Week Low	$1.07
Volume	22.76K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-33.85M
Gross Margin	0.00%

Recent ALDX Insider Trades

DOUGLAS RICHARD bought 70.00K (~$98.00K) on Mar 19, 2026.
Alfieri Michael bought 5.00K (~$7.10K) on Mar 18, 2026.
Alfieri Michael bought 2.50K (~$13.25K) on Aug 13, 2025.
Machatha Stephen sold 22.07K (~$113.71K) on Aug 11, 2025.
PERCEPTIVE ADVISORS LLC sold 3.40M (~$4.83M) on Apr 3, 2025.

Latest ALDX News

Aldeyra Therapeutics Shares Plunge 71% After Third FDA CRL on Reproxalap NDA — Mar 18, 2026
Aldeyra CEO Showcases Reproxalap Ahead of March 16 FDA PDUFA Decision — Feb 25, 2026

ALDX Analyst Consensus

2 analysts cover ALDX: 0 strong buy, 1 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $5.50.

Common questions about ALDX

Who is trading ALDX stock inside the company?: Recent ALDX insider activity includes DOUGLAS RICHARD bought 70.00K, Alfieri Michael bought 5.00K, Alfieri Michael bought 2.50K, Machatha Stephen sold 22.07K, and PERCEPTIVE ADVISORS LLC sold 3.40M. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ALDX?: Yes. Rallies tracks ALDX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ALDX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ALDX. It does not provide personalized investment advice.